v3.26.1
COLLABORATION AND LICENSE AGREEMENTS - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended
Apr. 30, 2024
Mar. 31, 2026
Mar. 31, 2025
Jun. 30, 2022
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2022
Apr. 30, 2025
Schedule of License and Collaboration Agreements [Line Items]                
Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001     $ 0.0001 $ 0.0001    
Total revenue   $ 212 $ 212   $ 858 $ 636    
Research and development   2,871 $ 5,725   19,597 41,507    
AbCellera Collaboration                
Schedule of License and Collaboration Agreements [Line Items]                
Research and development         0 400    
License                
Schedule of License and Collaboration Agreements [Line Items]                
Total revenue         800 600    
License Agreement | Sanofi                
Schedule of License and Collaboration Agreements [Line Items]                
Upfront payment       $ 3,000        
Aggregate development and regulatory milestone payments         43,000      
Obligation to payment upon maximum achievement of certain clinical and commercial milestones         150,000      
License Agreement | Sanofi | License Rights                
Schedule of License and Collaboration Agreements [Line Items]                
Transaction costs associated with asset acquisition             $ 100  
License Agreement | Sanofi | License Rights | IPR&D                
Schedule of License and Collaboration Agreements [Line Items]                
Research and development         $ 0 $ 0 $ 3,100  
Collaboration [Member]                
Schedule of License and Collaboration Agreements [Line Items]                
Total revenue   $ 200            
Johnson & Johnson | Securities Purchase Agreement                
Schedule of License and Collaboration Agreements [Line Items]                
Sale of stock, number of shares issued in transaction (in shares) 454,545              
Sale of stock, price per share (in dollars per share) $ 14.56              
Sale of stock, premium on stock price (as a percent) 10.00%              
Gross proceeds $ 6,600              
Allocated amounts 1,200              
Johnson & Johnson | Securities Purchase Agreement | Fair Value, Nonrecurring                
Schedule of License and Collaboration Agreements [Line Items]                
Fair value 5,400              
Johnson & Johnson | Securities Purchase Agreement | Measurement Input, Premium                
Schedule of License and Collaboration Agreements [Line Items]                
Allocated amounts 700              
Johnson & Johnson | Securities Purchase Agreement | Measurement Input, Discount for Lack of Marketability                
Schedule of License and Collaboration Agreements [Line Items]                
Allocated amounts $ 500              
Johnson & Johnson | Securities Purchase Agreement | Measurement Input, Price Volatility | Fair Value, Nonrecurring                
Schedule of License and Collaboration Agreements [Line Items]                
Measurement input 1.132              
Johnson & Johnson | Securities Purchase Agreement | Measurement Input, Risk Free Interest Rate | Fair Value, Nonrecurring                
Schedule of License and Collaboration Agreements [Line Items]                
Measurement input 0.0528              
Johnson & Johnson | License                
Schedule of License and Collaboration Agreements [Line Items]                
Collaboration agreement term 2 years              
Upfront payment               $ 500
Johnson & Johnson | License Agreement                
Schedule of License and Collaboration Agreements [Line Items]                
Collaboration agreement term 2 years